A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma

Ashley M Cimino-Mathews, Sangita Verma, Maria Cristina Figueroa-Magalhaes, Stacie C. Jeter, Zhe Zhang, Pedram Argani, Vered Stearns, Roisin Connolly

Research output: Contribution to journalArticle

Abstract

Objectives: Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. Methods: We searched clinical and pathology databases for patients with histologically confirmed MBC from 1999 to 2012. We estimated survival probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression. Results: Forty-five cases were identified, including chondroid (24%), spindled (20%), sarcomatoid (16%), squamous (11%), and mixed (29%) histologic subtypes. Median tumor size was 3 cm, with 86% grade III and 69% triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Most had negative lymph nodes, and two patients had metastases at diagnosis. Six patients received neoadjuvant therapy, with one pathologic complete response. All patients underwent surgery, 60% received adjuvant radiation, and 58% had adjuvant chemotherapy. Five-year recurrence-free survival was 64%; 5-year overall survival was 69%. Tumor size, history of breast cancer, and mixed histology were associated with inferior outcomes. Conclusions: We report one of the largest single-institution series of patients with MBC. MBC is associated with a poor prognosis, despite low nodal involvement. Most patients in this series had high-grade, triple-negative tumors and were treated with optimal therapy.

Original languageEnglish (US)
Pages (from-to)365-372
Number of pages8
JournalAmerican Journal of Clinical Pathology
Volume145
Issue number3
DOIs
StatePublished - Mar 1 2016

Fingerprint

Breast Neoplasms
Survival
Neoplasms
Clinical Pathology
Neoadjuvant Therapy
Progesterone Receptors
Adjuvant Chemotherapy
Estrogen Receptors
Histology
Lymph Nodes
Databases
Radiation
Neoplasm Metastasis
Recurrence
Therapeutics

Keywords

  • Metaplastic breast carcinoma
  • Sarcomatoid breast carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma. / Cimino-Mathews, Ashley M; Verma, Sangita; Figueroa-Magalhaes, Maria Cristina; Jeter, Stacie C.; Zhang, Zhe; Argani, Pedram; Stearns, Vered; Connolly, Roisin.

In: American Journal of Clinical Pathology, Vol. 145, No. 3, 01.03.2016, p. 365-372.

Research output: Contribution to journalArticle

Cimino-Mathews, Ashley M ; Verma, Sangita ; Figueroa-Magalhaes, Maria Cristina ; Jeter, Stacie C. ; Zhang, Zhe ; Argani, Pedram ; Stearns, Vered ; Connolly, Roisin. / A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma. In: American Journal of Clinical Pathology. 2016 ; Vol. 145, No. 3. pp. 365-372.
@article{857bdaf9efa447d4a19e6c118c4504f2,
title = "A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma",
abstract = "Objectives: Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. Methods: We searched clinical and pathology databases for patients with histologically confirmed MBC from 1999 to 2012. We estimated survival probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression. Results: Forty-five cases were identified, including chondroid (24{\%}), spindled (20{\%}), sarcomatoid (16{\%}), squamous (11{\%}), and mixed (29{\%}) histologic subtypes. Median tumor size was 3 cm, with 86{\%} grade III and 69{\%} triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Most had negative lymph nodes, and two patients had metastases at diagnosis. Six patients received neoadjuvant therapy, with one pathologic complete response. All patients underwent surgery, 60{\%} received adjuvant radiation, and 58{\%} had adjuvant chemotherapy. Five-year recurrence-free survival was 64{\%}; 5-year overall survival was 69{\%}. Tumor size, history of breast cancer, and mixed histology were associated with inferior outcomes. Conclusions: We report one of the largest single-institution series of patients with MBC. MBC is associated with a poor prognosis, despite low nodal involvement. Most patients in this series had high-grade, triple-negative tumors and were treated with optimal therapy.",
keywords = "Metaplastic breast carcinoma, Sarcomatoid breast carcinoma",
author = "Cimino-Mathews, {Ashley M} and Sangita Verma and Figueroa-Magalhaes, {Maria Cristina} and Jeter, {Stacie C.} and Zhe Zhang and Pedram Argani and Vered Stearns and Roisin Connolly",
year = "2016",
month = "3",
day = "1",
doi = "10.1093/ajcp/aqv097",
language = "English (US)",
volume = "145",
pages = "365--372",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - A clinicopathologic analysis of 45 patients with metaplastic breast carcinoma

AU - Cimino-Mathews, Ashley M

AU - Verma, Sangita

AU - Figueroa-Magalhaes, Maria Cristina

AU - Jeter, Stacie C.

AU - Zhang, Zhe

AU - Argani, Pedram

AU - Stearns, Vered

AU - Connolly, Roisin

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Objectives: Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. Methods: We searched clinical and pathology databases for patients with histologically confirmed MBC from 1999 to 2012. We estimated survival probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression. Results: Forty-five cases were identified, including chondroid (24%), spindled (20%), sarcomatoid (16%), squamous (11%), and mixed (29%) histologic subtypes. Median tumor size was 3 cm, with 86% grade III and 69% triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Most had negative lymph nodes, and two patients had metastases at diagnosis. Six patients received neoadjuvant therapy, with one pathologic complete response. All patients underwent surgery, 60% received adjuvant radiation, and 58% had adjuvant chemotherapy. Five-year recurrence-free survival was 64%; 5-year overall survival was 69%. Tumor size, history of breast cancer, and mixed histology were associated with inferior outcomes. Conclusions: We report one of the largest single-institution series of patients with MBC. MBC is associated with a poor prognosis, despite low nodal involvement. Most patients in this series had high-grade, triple-negative tumors and were treated with optimal therapy.

AB - Objectives: Metaplastic breast carcinomas (MBCs) are rare, aggressive cancers lacking targeted therapy. Here, we review the clinicopathologic features, treatment, and outcomes of patients with MBC treated at our institution. Methods: We searched clinical and pathology databases for patients with histologically confirmed MBC from 1999 to 2012. We estimated survival probabilities using the Kaplan-Meier method and evaluated prognostic factors using Cox regression. Results: Forty-five cases were identified, including chondroid (24%), spindled (20%), sarcomatoid (16%), squamous (11%), and mixed (29%) histologic subtypes. Median tumor size was 3 cm, with 86% grade III and 69% triple-negative for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2. Most had negative lymph nodes, and two patients had metastases at diagnosis. Six patients received neoadjuvant therapy, with one pathologic complete response. All patients underwent surgery, 60% received adjuvant radiation, and 58% had adjuvant chemotherapy. Five-year recurrence-free survival was 64%; 5-year overall survival was 69%. Tumor size, history of breast cancer, and mixed histology were associated with inferior outcomes. Conclusions: We report one of the largest single-institution series of patients with MBC. MBC is associated with a poor prognosis, despite low nodal involvement. Most patients in this series had high-grade, triple-negative tumors and were treated with optimal therapy.

KW - Metaplastic breast carcinoma

KW - Sarcomatoid breast carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84982133315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84982133315&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqv097

DO - 10.1093/ajcp/aqv097

M3 - Article

VL - 145

SP - 365

EP - 372

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -